Torisel

Torisel

File:Temsirolimus.png
Identifiers
CAS Number	162635-04-3
PubChem CID	6918289
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}

WikiDoc Resources for Torisel
Articles
Most recent articles on Torisel Most cited articles on Torisel Review articles on Torisel Articles on Torisel in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Torisel Images of Torisel Photos of Torisel Podcasts & MP3s on Torisel Videos on Torisel
Evidence Based Medicine
Cochrane Collaboration on Torisel Bandolier on Torisel TRIP on Torisel
Clinical Trials
Ongoing Trials on Torisel at Clinical Trials.gov Trial results on Torisel Clinical Trials on Torisel at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Torisel NICE Guidance on Torisel NHS PRODIGY Guidance FDA on Torisel CDC on Torisel
Books
Books on Torisel
News
Torisel in the news Be alerted to news on Torisel News trends on Torisel
Commentary
Blogs on Torisel
Definitions
Definitions of Torisel
Patient Resources / Community
Patient resources on Torisel Discussion groups on Torisel Patient Handouts on Torisel Directions to Hospitals Treating Torisel Risk calculators and risk factors for Torisel
Healthcare Provider Resources
Symptoms of Torisel Causes & Risk Factors for Torisel Diagnostic studies for Torisel Treatment of Torisel
Continuing Medical Education (CME)
CME Programs on Torisel
International
Torisel en Espanol Torisel en Francais
Business
Torisel in the Marketplace Patents on Torisel
Experimental / Informatics
List of terms related to Torisel

Temsirolimus is an intravenous drug for the treatment of renal cell carcinoma (RCC), developed by Wyeth Pharmaceuticals and approved by the FDA in late May 2007. It is a derivative of the macrolide sirolimus.

The drug is promising for RCC patients. A phase III clinical study of the drug showed a 49 percent increase in patients' median overall survival time (10.9 months). The drug was administered to patients who had received no prior systemic therapy; however, this study only included patients with a poor prognosis. The benefits of temsirolimus in patients with favorable or intermediate prognostic factors remains to be elucidated.